Patents by Inventor Viet-Anh Anne Horgan
Viet-Anh Anne Horgan has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11040969Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: GrantFiled: July 17, 2019Date of Patent: June 22, 2021Assignee: BENEVOLENTAI CAMBRIDGE LIMITEDInventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Patent number: 10988473Abstract: The invention relates to an improved process for the synthesis of (3S, 4S)-tetrahydrofuran-3-yl 4-isopropyl-6,7-dihydro-3H-imidazo[4,5-c]pyridine-5(4H)-carboxylate, and pharmaceutically acceptable salts thereof, such as the methanesulphonic acid salt.Type: GrantFiled: October 25, 2017Date of Patent: April 27, 2021Assignee: BENEVOLENTAl CAMBRIDGE LIMITEDInventors: Viet-Anh Anne Horgan, Olof Haglund, Lee Patient, Edward Savory, Michael Higginbottom, Michael Ashwood
-
Publication number: 20190359611Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: ApplicationFiled: July 17, 2019Publication date: November 28, 2019Applicant: BENEVOLENTAI CAMBRIDGE LIMITEDInventors: Edward SAVORY, Michael HIGGINBOTTOM, Kathryn OLIVER, Viet-Anh Anne HORGAN
-
Patent number: 10399973Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: GrantFiled: December 29, 2017Date of Patent: September 3, 2019Assignee: BENEVOLENTAI CAMBRIDGE LIMITEDInventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Publication number: 20180118744Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: ApplicationFiled: December 29, 2017Publication date: May 3, 2018Applicant: PROXIMAGEN LIMITEDInventors: Edward SAVORY, Michael HIGGINBOTTOM, Kathryn OLIVER, Viet-Anh Anne HORGAN
-
Patent number: 9890160Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: GrantFiled: October 27, 2016Date of Patent: February 13, 2018Assignee: PROXIMAGEN LIMITEDInventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Publication number: 20170044157Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: ApplicationFiled: October 27, 2016Publication date: February 16, 2017Inventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Patent number: 9493457Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: GrantFiled: April 13, 2015Date of Patent: November 15, 2016Assignee: Proximagen LimitedInventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Publication number: 20150218161Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: ApplicationFiled: April 13, 2015Publication date: August 6, 2015Inventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Patent number: 9035066Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: GrantFiled: October 25, 2013Date of Patent: May 19, 2015Assignee: Proximagen LimitedInventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Publication number: 20140121219Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: ApplicationFiled: October 25, 2013Publication date: May 1, 2014Applicant: Proximagen LimitedInventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Patent number: 8569338Abstract: The present invention relates to a method for the treatment or prevention of inflammation, an inflammatory disease, an immune or an autoimmune disorder, which comprises administering to a mammal in need of such treatment an effective amount of a compound compound of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity.Type: GrantFiled: August 6, 2012Date of Patent: October 29, 2013Assignee: Proximagen Ltd.Inventors: Edward Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Publication number: 20120302583Abstract: The present invention relates to a method for the treatment or prevention of inflammation, an inflammatory disease, an immune or an autoimmune disorder, which comprises administering to a mammal in need of such treatment an effective amount of a compound compound of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity.Type: ApplicationFiled: August 6, 2012Publication date: November 29, 2012Applicant: PROXIMAGEN LIMITEDInventors: Edward Daniel Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Patent number: 8263616Abstract: The present invention relates to compounds of formula (I), and their pharmaceutically acceptable salts, solvates, hydrates, geometrical isomers, tautomers, optical isomers or N-oxides, which are inhibitors of SSAO activity. The invention further relates to pharmaceutical compositions comprising these compounds and to the use of these compounds for the treatment of medical conditions wherein inhibition of SSAO activity is beneficial, such as inflammatory diseases and immune disorders.Type: GrantFiled: September 16, 2009Date of Patent: September 11, 2012Assignee: Proximagen LtdInventors: Edward Daniel Savory, Michael Higginbottom, Kathryn Oliver, Viet-Anh Anne Horgan
-
Patent number: 8093248Abstract: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.Type: GrantFiled: December 5, 2008Date of Patent: January 10, 2012Assignee: AstraZeneca AB (PUBL)Inventors: Joseph W. Boyd, Giles A. Brown, Michael Higginbottom, Viet-Anh Anne Horgan (Nee Nguyen), Jaqueline Ouzman, Iain Simpson
-
Publication number: 20110275637Abstract: The present invention relates to new compounds of formula (I), to pharmaceutical compositions comprising these compounds and to the use of these compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.Type: ApplicationFiled: June 4, 2009Publication date: November 10, 2011Inventors: Emma Chapman, Michael Higginbottom, Viet-Anh Anne Horgan (nee Nguyen), James Horton, Iain Simpson, Charles Tyzack
-
Publication number: 20090281087Abstract: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.Type: ApplicationFiled: December 5, 2008Publication date: November 12, 2009Applicant: Biovitrum ABInventors: Joseph W. Boyd, Giles A. Brown, Michael Higginbottom, Viet-Anh Anne Horgan (nee Nguyen), Jaqueline Ouzman, Iain Simpson
-
Publication number: 20090203695Abstract: The present application relates to new compounds of formula (I), to pharmaceutical compositions comprising the compounds, to processes for their preparation, and to the use of the compounds as leptin receptor modulator mimetics in the preparation of medicaments against conditions associated with weight gain, type 2 diabetes and dyslipidemias.Type: ApplicationFiled: December 5, 2008Publication date: August 13, 2009Applicant: Biovitrum ABInventors: Michael Higginbottom, Viet-Anh Anne Horgan (nee Nguyen), Iain Simpson
